Trump signs order to boost U.S. drug manufacturing

chairman Donald Trump On Monday, an executive order was signed to encourage the prescription drug manufacturing in the US, with the path for pharmaceutical companies to create new production sites as a possible tariff on the loom of drugs imported for pharmaceutical companies.

The order directs the food and drug administration to eliminate unnecessary requirements, streamlines reviews and to work with domestic drug manufacturers to reduce the amount of time to approve manufacturing plants in the US “” Provide earlier support before coming to features ” A White House Fact Sheet,

This also instructs the agency to increase inspection fees for foreign manufacturing plants, improve the enforcement of active-domestic source reporting by foreign producers and to consider publicly listed features that do not comply with.

The White House estimates that it may take five to 10 years to create a new manufacturing capacity for pharmaceuticals, which is called “unacceptable” from the national-protection point of view.

Trump said in the fact sheet, “We do not want to buy our pharmaceuticals from other countries because if we are in war, we are in a problem, we want to be able to make our own,” Trump said in the fact sheet. “As we invest in the future, we will permanently bring back our medical supply chains home. We will produce our medical supply, pharmaceuticals and treatment in the United States.”

The order would allow the FDA to conduct more inspection of new manufacturing sites with the same resources, the agency’s commissioner, Marti Makari on Monday asked reporters. The FDA will also increase the inspection of foreign drug features, which will switch to “surprise” abroad, he said.

“We had this crazy system in the United States where the American Pharma manufacturer … is inserted through the ringer with inspection, and foreign sites get very easy with Scheduled Tips, while we have stunning trips,” Makeri said.

Trump’s order also relates to drugs and their content to “speed up building facilities” to the environmental protection agency. And, it ensures that federal agencies issuing permits for a domestic pharmaceutical manufacturing facility nominate a single point-off-contacts to coordinate applications, as well as with the support of the White House Office of Management and Budget.

This order comes ahead of Trump’s planned tariff on imported pharmaceuticals in the US, which are imports in the potential levy – and efforts to make goodwill with the President – already there Promoted a new wave of domestic manufacturing investment Like drug manufacturers Ellie lily, Johnson & Johnson And Abbi,

Trump told reporters on Monday that he would announce a drug-specific tariff within the next two weeks. Their administration exposure In April, it opened an investigation of a so-called section 232 how to import some pharmaceuticals affects national security-a step widely seen as a preface to start tariffs on drugs.

Some pharmaceutical companies are starting to push back on Trump’s plans. For example, Fizer CEO Albert Borla said last week that Tariff Danger Stopping Company By making further American investments in research and development and manufacturing.

US manufacturing in the drug industry has shrunk a lot in recent decades. The production of most so -called active ingredients in drugs has moved into China and other countries, roughly due to low cost for labor and other parts of the process, Food and Drug Administration,

The US imported $ 203 billion in pharmaceutical products alone in 2023, with 73% according to Europe, mainly according to Ireland, Germany and Switzerland, Analysis Consulted by consulting firm EY.

According to the April 1 release, re -starting manufacturing can help in strengthening the drug supply chain, which can reduce the risk of disruptions GlobaldataA data and analytics company. Nevertheless, it can increase production costs and drug prices, increases the concerns of strength, Globalada said.